Abstract 1753P
Background
Myxofibrosarcoma (MFS) are malignant tumors usually diagnosed in the extremities or trunk of elderly patients. Prognosis in this sarcoma subtype is dismal due to high risk of local recurrence. Our aim was to analyze the treatment results of patients (pts) diagnosed with localized myxofibrosarcoma, taking into account also surgical complications.
Methods
245 pts (51% male) with locally advanced myxofibrosarcoma treated in 2015-2020 were included in this retrospective analysis. Data on tumor characteristic and long-term survival and surgical complications were collected. Kaplan-Meier estimator with log-rank test was used for survival analysis. Median follow-up was 70 months (95%CI 67.2-79.7).
Results
The mean age was 63 years. 65% of the pts had no prior treatment, and 24% were referred after non-radical excision outside our center. Median size of the tumor was 9 cm (SD:6), 73% were high grade, 63% of cases were located on the lower limb (most often on the thigh). 82% had perioperative radiotherapy (72% preoperative). 22% of pts had preoperative chemotherapy. 76% pts underwent R0 resection, the others - R1. 56 pts (22%) had local recurrence and 29 of them had had another radical surgery, most of them extremity amputation (20 pts). 32% pts (79) developed metastases. Median OS was 115 months (95%CI 90.3-NA), while disease free-survival and local recurrence free survival (were 53.5 CI: (39.7 - NA) and not reached, respectively. In a multivariate analysis neoadjuvant radiotherapy was associated with longer LRFS (HR 0.36, 95%CI 0.21-0.65). T3 or T4 tumors and grade 2 or 3 tumors were associated with shorter DFS. Preoperative chemotherapy did not improve DFS (HR 0.82, 95%CI 0.51-1.33). 103 (42%) patient had complications after surgery resulting in prolonged wound healing, 40 of them had more than one complications, 10% patient required hospitalization due to complications, and 8.5% had another surgery for treatment of the complications.
Conclusions
Myxofibrosarcoma is a rare sarcoma subtype, local recurrences after adequate surgery are relatively common and most patient require adjuvant treatment and close follow-up. Treatment should be conducted in experienced sarcoma center with access to multidisciplinary team.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1751P - Clinical and survival data of 336 myxoid liposarcoma patients: The Gustave Roussy experience
Presenter: Tarek Assi
Session: Poster session 06
1752P - A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
Presenter: Olayode Babatunde
Session: Poster session 06
1755P - Multimodal therapy in first line treatment of very high risk Ewing sarcoma patients: Results of the French prospective multicenter COMBINAIR3 phase II trial
Presenter: Valerie Laurence
Session: Poster session 06
1756P - A phase I/II trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma
Presenter: J Andrew Livingston
Session: Poster session 06
1757P - Proceedings of the think tank for osteosarcoma medical advisory board meeting
Presenter: Sant Chawla
Session: Poster session 06
1758P - Real-world efficacy of imatinib in patients with advanced GIST: The LRG registry
Presenter: Gahyun Gim
Session: Poster session 06
1759P - Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor
Presenter: Jian Li
Session: Poster session 06
1760P - Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC+ network
Presenter: Vincent Hautefeuille
Session: Poster session 06
1761P - Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC+ network
Presenter: Charlotte Cuvelier
Session: Poster session 06